Peter Attia's Outlive: Summary for European readers

Peter Attia is a Canadian-born physician in the US (MD from Stanford, surgical training at Johns Hopkins) and one of the best-known voices in longevity. His 2023 book "Outlive: The Science and Art of Longevity", written with the journalist Bill Gifford, was a bestseller ^[8]. It still shapes how a lot of people think about long, healthy living. A German edition came out in 2024 as "Outlive: Wie wir länger und besser leben können, als wir denken" (Ullstein).

He runs a private practice in the US. The patient list is tiny and very wealthy. That splits opinions fast: he reads the evidence carefully, but his style of care is priced out of reach for almost everyone.

His real gift to the rest of us sits in the mental models. Outlive gives you clean ways to think about healthspan (the years you are not just alive but healthy) versus lifespan. It also gives you sharper questions to bring to your own doctor.

Attia openly rejects the old Marcus Welby model of medicine: the kindly family doc who waits for symptoms, then reacts. That, he argues, is exactly the gap Medicine 3.0 has to close.

Attia's central claim is simple. By his count, over 80% of deaths in non-smokers over 50 come from four clusters of disease ^[8]. He calls them the Four Horsemen.

1. Atherosclerotic cardiovascular disease (ASCVD), meaning heart attack and stroke. It is the top cause of death in Germany. Attia's move is to start intervening very early. He steers by blood markers: ApoB (the number of cholesterol-carrying particles) ^[5], lipoprotein(a) or Lp(a) (a mostly inherited particle that raises risk) ^[4], LDL-C (classic "bad" cholesterol) and hsCRP (a marker of low-grade inflammation). For the full lipid logic, see our ApoB and Lp(a) guide.

2. Cancer. The aim is to catch it earlier. Colonoscopy from 40 is Attia's private-practice recommendation, not a public guideline. For comparison, the US Preventive Services Task Force (USPSTF) starts at 45. In Germany, statutory health insurance (GKV) has covered screening colonoscopy for men and women alike from age 50 since 1 April 2025 (G-BA decision of 16 January 2025). Going earlier than that is a self-pay choice. Attia also adds regular skin checks (GKV pays for a skin cancer screening every 2 years from age 35), plus whole-body MRI if you carry higher risk, which you pay for yourself. How well that works is genuinely debated. More tests also mean more false alarms.

3. Neurodegenerative disease, such as Alzheimer's, Parkinson's, and dementia. The levers: heart and blood vessel health, mental stimulation, social contact, sleep, and training.

4. Metabolic dysfunction, meaning type 2 diabetes, fatty liver, and metabolic syndrome. Strong focus on insulin sensitivity, belly fat around the organs, and how your body handles sugar.

For the average patient, the concepts are useful. The intensity of Attia's screening plan is not realistic for most people, and for low-risk readers it is not strongly backed by evidence either.

The Four Horsemen through a female lens

The Four Horsemen apply to women too, but the weighting shifts after menopause. Cardiovascular risk speeds up as estrogen falls. A history of preeclampsia (a pregnancy disorder with high blood pressure and organ strain, usually protein in the urine) comes with roughly 2x the future risk of coronary heart disease (CHD) ^[11] (see our women's guide). Alzheimer's hits women disproportionately, partly for biological reasons. ApoB and Lp(a) matter just as much (see our ApoB and Lp(a) guide). So does early DEXA screening from 50 for osteoporosis.

Medicine 3.0 is Attia's name for proactive, individualised medicine that puts prevention before treatment and treats healthspan, not just lifespan, as the goal. He splits medical history into three eras to make the point. His claim: today's standard of care is reactive, and that is the wrong setting for longevity work.

Medicine 2.0 works, but it mostly reacts. This is the Marcus Welby mode Attia keeps pushing back against. Medicine 3.0 puts prevention before treatment and treats the patient as a partner, not a passive case.

What Outlive actually tells you to do. The last part of the book turns Medicine 3.0 into five tactical areas: exercise, nutrition, sleep, emotional health, and "exogenous molecules" (drugs, hormones, supplements) ^[8]. Exercise gets by far the most weight. Attia calls it the most powerful longevity drug we have. On nutrition he is more cautious than most diet books. The book ends on emotional health, including his own story, because a long life you don't enjoy misses the point.

For the German system, this overlaps with Vorsorge (the preventive check-ups covered by GKV statutory insurance). But Medicine 3.0 at Attia's intensity is mostly a self-pay affair, or something you find in specialised private clinics (see our self-pay guide).

The Centenarian Decathlon is Attia's planning exercise: write down the 10 physical things you want to still be able to do in your Marginal Decade, then train backwards from there today. The Marginal Decade is his term for the final ten years of your life, whenever those land. Age 90 is a reasonable planning proxy, but the concept is about the quality of that last decade, not a fixed calendar age. It is arguably the most useful idea in the whole book.

Attia's version: list 10 physical capacities. The canonical examples from Outlive (Ch. 12) are mostly functional, not athletic:

• Hike 1.5 miles on a hilly trail
• Get up off the floor with one arm (ideally no hands). How well you sit and rise from the floor predicts all-cause mortality ^[3]
• Pick up a young child off the floor (Attia in interviews specifies ~14 kg / 30 lb)
• Carry two ~2.3 kg (5 lb) bags of groceries for five blocks
• Lift a ~9 kg (20 lb) suitcase into an overhead bin
• Balance on one leg with eyes open for 30 seconds
• Have sex
• Climb four flights of stairs in three minutes
• Open a jar
• Do 30 consecutive jump-rope skips

These are examples, not a fixed canon. The list is deliberately personal. Pick the capacities that matter to you.

Why the back-calculation matters. Physical performance fades with age. To still hit these in your Marginal Decade, you need to be able to do clearly more today. Attia does not use a blanket "double at 50" rule, even though that shorthand gets repeated everywhere. In Outlive he back-calculates from known age-related decline curves that differ by capacity. VO2 max (your body's ceiling on oxygen uptake during hard exercise) drops roughly 10 % per decade, and faster after 50 to 60. Muscle strength and power decline at their own rates. You plan backward from your Marginal Decade target along the curve for each capacity. Sometimes that lands at roughly double today, sometimes more, sometimes less.

For VO2 max, Attia's longevity benchmark is the "elite" tier: the top ~2.3%, at or above the 97.7th percentile, in the Mandsager 2018 fitness data he cites ^[2]. Paraphrasing Outlive and his Drive podcast episodes on VO2 max: he has repeatedly set the goal at the elite cut-off for someone roughly a decade younger than you, sometimes two decades.

The training priorities that fall out: strength, stability, Zone 2 aerobic efficiency, and VO2 max. Attia's weekly structure is concrete:

• Zone 2 cardio: about 3 hours per week as a floor for patients, and 3-4 hours (in sessions of 45 minutes or more) as his personal target
• One 4x4 VO2 max session: four rounds of four minutes hard, three minutes easy active recovery (the Norwegian protocol from Helgerud's group ^[1])
• 2-3 strength sessions

The goal is not isolated muscle size or marathon times. For the protocols behind Zone 2 and VO2 max, see our Zone 2 and VO2 max training guide.

Attia's core lesson is free: picture your life at 85 and plan backwards from there. It is the single most valuable tool in the whole book. On top of that, you can use his framework at three levels of effort. Pick the one that fits your budget and risk profile, not the most expensive option you can afford.

Free or low effort:

• Do the Centenarian Decathlon exercise. Write down your 10 capacities.
• Aim your training at those targets (strength, Zone 2 cardio, HIIT, mobility)
• Use the GKV Vorsorge you already have (from age 35, every 3 years)

Medium effort (self-pay):

• Expanded blood panel with ApoB, Lp(a), hsCRP, HbA1c, fasting insulin (about 100 to 250 euros)
• VO2 max test at a sports-medicine clinic (100 to 200 euros)
• DEXA scan (50 to 120 euros) for bone and body composition
• Carotid intima-media measurement (70 to 150 euros)
• A private longevity consult (150 to 400 euros per visit)

High effort (benefit debated):

• Whole-body MRI (800 to 2,500 euros). For low-risk patients, false alarms often outweigh the upside (see our whole-body MRI guide).
• CGM (continuous glucose monitor) without diabetes (50 to 150 euros per month). Whether it helps non-diabetics is genuinely open (see our CGM without diabetes guide).
• Coronary calcium score (150 to 300 euros)

Your 12 months on the Attia framework

A realistic monthly roadmap for Germany, Austria and Switzerland (DACH):

• Month 1: write your own Centenarian Decathlon (10 capacities for your Marginal Decade). No spending.
• Month 2: book GKV Vorsorge (free, ages 35+ every 3 years) plus a fasting lipid panel.
• Month 3: IGeL add-ons (self-pay tests at a German practice): ApoB, Lp(a), hsCRP and fasting insulin (about 100 to 250 euros at Synlab, Limbach, Lademannbogen or IMD Berlin). You only need to test Lp(a) once in your life, because your genes largely set it ^[4].
• Month 6: VO2 max test at a sports-medicine practice (about 100 to 200 euros) plus a baseline DEXA scan for bone density and body composition (about 50 to 120 euros per scan). Attia scans his patients roughly once a year. People actively working on body composition get scanned every 3 to 6 months. His general bias: get an early baseline instead of waiting for symptoms.
• Month 9: coronary calcium score if your cardiovascular risk profile points to it (about 150 to 300 euros).
• Month 12: repeat the Decathlon exercise and compare your lifts, VO2 max, and ApoB to baseline. Adjust the training block.

Decathlon targets by decade

A practical shorthand scaling relative to your Marginal Decade target. Attia himself back-calculates from capacity-specific decline curves rather than a single multiplier, so treat these as planning approximations:

• At 50: aim for roughly 2x the Marginal Decade target
• At 60: roughly 1.5x
• At 70: roughly 1.2x
• VO2 max: start by aiming for the "elite" tier for your current age (top ~2.3%, at or above the 97.7th percentile in Mandsager 2018, the data Attia cites ^[2]). Attia's own bar is higher: the elite cut-off for someone roughly a decade younger, sometimes two. That buffer matches the ~10% decline per decade on the way to your Marginal Decade floor.
• Grip strength: in the PURE study (grip tests on about 125,000 healthy adults in 21 countries), median grip for adults from Europe and North America was about 49 kg (men) and 30 kg (women) at ages 41 to 50, and about 46 kg / 27 kg at 51 to 60 ^[10]. These are population medians that some people use as functional targets. They are not guideline minimums. The EWGSOP2 cut-offs for sarcopenia (age-related muscle loss) sit much lower: <27 kg for men, <16 kg for women ^[7]. Falling below them flags probable sarcopenia. A doctor confirms it only if a scan also shows low muscle mass or quality.

Anecdote vs trial data: how to read Outlive

A lot of Attia's most striking advice (early colonoscopy, intensive screening, hormone protocols, rapamycin) rests on observational data and his clinical experience with a small, wealthy patient panel. It does not rest on randomised controlled trials (RCTs). Whole-body MRI, for example, has no RCT showing it lowers hard outcomes like death or heart attack in low-risk people. That is not a knockout argument against him. Many longevity questions will never get clean RCT answers, because they need 30-year follow-up. But his personal anecdotes are not the same evidence tier as the lipid trials he cites ^[5]. Keep the strong-evidence pieces (ApoB as a cause of heart disease ^[5], fitness and mortality data ^[2]) apart from the personal-practice pieces. When you adopt a tip from the book, ask: does this rest on a randomised trial, or on Attia's experience with a few very wealthy patients?

Where Attia stands on rapamycin

Attia has talked publicly for several years about taking rapamycin off-label (outside its approved use). Through 2023-2024 he also described pausing or cutting back his own use, citing mouth sores and unclear signs of benefit. In AMA #76 (his Ask Me Anything podcast episode of 27 October 2025), rapamycin stays in his "promising" longevity-drug category.

Then came RAPA-EX-01, the first placebo-controlled trial pairing weekly rapamycin with exercise, in 40 adults aged 65 to 85. There, 6 mg a week for 13 weeks did not improve training gains, may have slightly blunted them, and caused more side effects, including one serious infection that was possibly drug-related ^[9]. In his 2 May 2026 commentary on the trial, Attia still calls himself "curious, cautiously interested, and nowhere near ready to close the book" on rapamycin. His current public position is open, not a firm stop.

The PEARL trial (Aging, April 2025) was run by the telehealth company AgelessRx, using compounded rapamycin (mixed by a pharmacy, not a branded product). It missed its primary endpoint: less visceral fat, the fat packed around your organs ^[6]. A subgroup analysis split by sex found positive signals for lean mass and self-reported pain in women taking 10 mg per week. The trial was not sized to test that, so treat it as a lead for future studies, not a confirmed effect. See our rapamycin guide.